Is Molina Healthcare, Inc. (MOH) Stock a Sell after John Molina’s Insider Deal?; Genesco (GCO) Sentiment Is 1.13

An insider of the company Molina Healthcare Inc, John Molina also its director, disclosed his trade activities with the (SEC) on February 28, 2018. As reported in the document, John had unloaded 20,480 shares of the stock exchange listed company. The total insider transaction was worth $1,500,858 U.S. Dollars. At the time of the deal the price of a share was $73.3. This is not his first insider trade, in the last 30 days, he sold another 84,745 shares worth $6,551,494 USD. John Molina now indirectly has rights to 2335343 shares. He also directly has rights to 11154 shares. In total he holds a stake of 3.93%.

Genesco Inc. retails and wholesales footwear, apparel, and accessories. The company has market cap of $782.59 million. The companyÂ’s Journeys Group segment offers footwear and accessories through the Journeys, Journeys Kidz, Shi by Journeys, Little Burgundy, and Underground by Journeys retail stores, as well as through e-commerce and catalogs for young men, women, and children. It currently has negative earnings. The Company’s Schuh Group segment operates Schuh retail footwear stores that offer casual and athletic footwear for men and women, as well as sells footwear through e-commerce.

Since September 5, 2017, it had 0 buys, and 28 sales for $52.39 million activity. Another trade for 250 shares valued at $18,633 was made by ROMNEY RONNA on Friday, December 15. ORLANDO STEVEN J had sold 1,500 shares worth $109,155 on Monday, February 26. On Wednesday, October 11 DENTINO WILLIAM sold $1.44 million worth of Molina Healthcare, Inc. (NYSE:MOH) or 22,500 shares. 21,650 Molina Healthcare, Inc. (NYSE:MOH) shares with value of $2.00 million were sold by MOLINA JOHN C. MOLINA J MARIO MD had sold 15,000 shares worth $1.02M on Tuesday, October 3. $256,931 worth of Molina Healthcare, Inc. (NYSE:MOH) was sold by BAYER TERRY. Another trade for 5,224 shares valued at $352,098 was sold by Barlow Jeff D.

Among 21 analysts covering Molina Healthcare (NYSE:MOH), 7 have Buy rating, 3 Sell and 11 Hold. Therefore 33% are positive. Molina Healthcare has $105 highest and $45 lowest target. $75.94’s average target is 5.03% above currents $72.3 stock price. Molina Healthcare had 54 analyst reports since July 31, 2015 according to SRatingsIntel. As per Friday, July 31, the company rating was upgraded by Stifel Nicolaus. The stock of Molina Healthcare, Inc. (NYSE:MOH) earned “Hold” rating by Goldman Sachs on Wednesday, January 3. As per Thursday, August 17, the company rating was upgraded by Morgan Stanley. As per Monday, November 2, the company rating was maintained by Barclays Capital. The firm has “Buy” rating given on Friday, November 3 by Piper Jaffray. The firm has “Overweight” rating by Piper Jaffray given on Wednesday, January 4. The firm has “Hold” rating given on Thursday, February 16 by Stifel Nicolaus. The firm has “Hold” rating given on Thursday, December 15 by Jefferies. The rating was maintained by Barclays Capital on Tuesday, March 21 with “Equal-Weight”. The firm has “Buy” rating by Jefferies given on Tuesday, September 13.

Analysts await Molina Healthcare, Inc. (NYSE:MOH) to report earnings on May, 1. They expect $0.84 earnings per share, down 42.86% or $0.63 from last year’s $1.47 per share. MOH’s profit will be $50.14 million for 21.52 P/E if the $0.84 EPS becomes a reality. After $0.34 actual earnings per share reported by Molina Healthcare, Inc. for the previous quarter, Wall Street now forecasts 147.06% EPS growth.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program in the United States. The company has market cap of $4.32 billion. It operates through three divisions: Health Plans, Molina Medicaid Solutions, and Other. It currently has negative earnings. The Health Plans segment operates health plans in 12 states.

Investors sentiment increased to 1.08 in Q3 2017. Its up 0.04, from 1.04 in 2017Q2. It increased, as 43 investors sold Molina Healthcare, Inc. shares while 61 reduced holdings. 23 funds opened positions while 89 raised stakes. 58.60 million shares or 8.44% more from 54.04 million shares in 2017Q2 were reported. Lazard Asset Management Lc reported 10,015 shares. Credit Agricole S A stated it has 1,305 shares. 8,520 are owned by Alpha Windward Limited Com. Amalgamated Natl Bank, New York-based fund reported 6,056 shares. Ubs Asset Mngmt Americas Incorporated holds 0% or 33,049 shares. Moreover, Hanseatic Mngmt Services Incorporated has 0% invested in Molina Healthcare, Inc. (NYSE:MOH). Rudman Errol M invested 1.97% in Molina Healthcare, Inc. (NYSE:MOH). Bancorp Of Ny Mellon accumulated 717,124 shares or 0.01% of the stock. Aperio Gru Ltd stated it has 0.01% in Molina Healthcare, Inc. (NYSE:MOH). 252,373 are held by Nomura Inc. Aqr Capital Mngmt has invested 0.03% in Molina Healthcare, Inc. (NYSE:MOH). Hussman Strategic Advisors Inc invested in 0.02% or 1,200 shares. Pnc Grp stated it has 1,463 shares. Citigroup invested in 79,100 shares or 0% of the stock. Fmr Ltd Llc accumulated 0% or 373,071 shares.

The stock decreased 1.05% or $0.77 during the last trading session, reaching $72.3. About 878,388 shares traded. Molina Healthcare, Inc. (NYSE:MOH) has risen 48.61% since March 1, 2017 and is uptrending. It has outperformed by 31.91% the S&P500.

The stock decreased 0.76% or $0.3 during the last trading session, reaching $39.3. About 379,333 shares traded. Genesco Inc. (GCO) has declined 26.87% since March 1, 2017 and is downtrending. It has underperformed by 43.57% the S&P500.

Ratings analysis reveals 67% of Genesco’s analysts are positive. Out of 3 Wall Street analysts rating Genesco, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. GCO was included in 3 notes of analysts from September 2, 2016. The firm has “Neutral” rating given on Friday, September 2 by Robert W. Baird. Susquehanna initiated the shares of GCO in report on Friday, September 16 with “Positive” rating. CL King downgraded Genesco Inc. (NYSE:GCO) on Wednesday, October 19 to “Buy” rating.

Analysts await Genesco Inc. (NYSE:GCO) to report earnings on March, 9. They expect $2.08 EPS, down 3.26% or $0.07 from last year’s $2.15 per share. GCO’s profit will be $41.42M for 4.72 P/E if the $2.08 EPS becomes a reality. After $1.02 actual EPS reported by Genesco Inc. for the previous quarter, Wall Street now forecasts 103.92% EPS growth.